Phases, active trials: Phase 1: 13, Phase 2: 9, Phase 3: 10, Other: 55
Bayer's pharmaceutical pipeline is concentrated in oncology, cardiovascular disease, and an emerging radioligand therapy (RLT) platform. In oncology, Nubeqa (darolutamide) is an approved androgen receptor inhibitor for non-metastatic and metastatic castration-resistant prostate cancer, with ongoing trials in earlier-line settings. Vitrakvi (larotrectinib) and tepotinib provide kinase inhibitor coverage in TRK-fusion and MET-exon-14 cancers respectively. Bayer's radiopharmaceutical ambitions are reflected in Xofigo (radium-223) for bone-metastatic prostate cancer and a pipeline of targeted RLTs in collaboration with external partners. In cardiovascular, Kerendia (finerenone) for chronic kidney disease with type 2 diabetes, Verquvo (vericiguat) for heart failure, and next-generation Factor XIa inhibitor asundexian represent a deep late-stage CV portfolio. Xarelto (rivaroxaban) continues to generate new indication trials.
- Oncology (prostate, TRK-fusion, radioligand)
- Cardiovascular (Factor Xa/XIa, heart failure)
- Renal / cardiorenal (CKD, finerenone)
- Ophthalmology (VEGF-A/C/D)
- Women's health
- Nubeqa (darolutamide): AR inhibitor, prostate cancer
- Kerendia (finerenone): mineralocorticoid receptor antagonist, CKD/T2D
- Xarelto (rivaroxaban): Factor Xa, thrombosis/AF
- Vitrakvi (larotrectinib): TRK inhibitor, TRK-fusion cancers
- Verquvo (vericiguat): sGC stimulator, heart failure
- Asundexian: Factor XIa inhibitor, stroke prevention
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088)… NCT06760819 | Primary completion moved at least 1 year 11 months later | Recruiting |
8 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Learn More About How Well the Study Treatment Finerenone Works, How… NCT05196035 | Apr 10, 2027 · Estimated | Phase 3 |
This is the only one due in that window. See the calendar →
Monitor the Bayer pipeline daily
Get a daily digest when Bayer registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Chronic Kidney Disease | 8 |
| Hemophilia A | 6 |
| Type 2 Diabetes Mellitus | 5 |
| Advanced Solid Tumors | 3 |
| Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 3 |
| Non-metastatic Castration-resistant Prostate Cancer | 3 |
| Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 3 |
| Children | 2 |
Bayer's asundexian Factor XIa program is a closely watched anticoagulation alternative to direct oral anticoagulants, major Phase 3 readouts are expected in stroke prevention. Their Nubeqa (darolutamide) earlier-line prostate cancer trials generate competitive intelligence directly relevant to enzalutamide and apalutamide programs at competing firms.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bayer's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Bayer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Bayer pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is… NCT06452277 | Recruiting | Enrollment reduced: 555 → 444 participants | 2026-10-16 |
| A Methodological Study to Learn More About Kidney Function in Healthy People… NCT07368712 | Recruiting | Enrollment increased: 50 → 58 participants | 2026-10-15 |
| An Observational Study, Called FINEXPLORER, to Learn More About How Well… NCT07554469 | Recruiting | Study completion pushed from Apr 30, 2029 to May 31, 2029 | 2026-10-15 |
| An Observational Study to Learn More About How Safe Finerenone is and How Well… NCT06763146 | Active, Not Recruiting | Study completion pushed from Sep 30, 2026 to Oct 31, 2026 | 2026-10-15 |
| A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition… NCT07235462 | Recruiting | Study completion moved earlier from Jul 3, 2028 to Apr 30, 2028 | 2026-10-09 |
Each trial page shows every change DataLookout has recorded for that trial.